纤溶酶原激活物及其抑制剂-1的血浆含量测定在急性肺血栓栓塞症中的意义

目的探讨在急性肺血栓栓塞症(APE)发病中的组织型纤溶酶原激活物(tPA)及其抑制剂-1(PAI-1)的血浆含量、作用及其该病诊断中的意义。方法，对44例APE患者和56例健康正常对照者应用酶联免疫吸附双抗体夹心法(ELISA法)定量测定血浆tPA和PAI-1抗原水平。结果与正常对照组(tPA含量为11．05ng／ml和PAI-1含量为61．31ng／m1)相比，APE组的IPA含量(33．88ng／ml)和PAI-1含量(111．50ng／ml)较高，两组间差异有显著性。在急性肺血栓栓塞症的疾病诊断中，tPA和PAI-1的血浆含量合理诊断截断点分别为21．7ng／ml和79．4ng／ml.结论急性肺血栓栓塞症的发病是由于PAI-1抗原产生和释放增多，而非tPA抗原释放或产生不足所致．tPA和PAI-1抗原血浆含量测定在APE的疾病诊断中具有要意义。

Value of measuring plasma concentration of plasminogen activator and its inhibitor-1 in acute pulmonary thromboembolism

Objective To investigate the significance of plasminogen activator(tPA) and plasminogen activator inhibitor-1(PAI-1)in acute pulmonary thromboembolism(APE).Methods The levels of PAI-1 and tPA were measured by a commercially available enzyme-linked immunosorbent assay(ELISA)in 44 APE patients and 56 health control persons.Results Compared with tPA 11.05 ng/ml and PAI-1 antigen 61.31 ng/ml in healthy control group,APE patients had higher levels of tPA antigen 33.88 ng/ml and PAI-1 antigen 111.50 ng/ml.In the diagnosis of pulmonary thromboembolism,tPA 21.7 ng/ml and PAI-1 79.4 ng/ml were the cut-off points.Conclusion Increased PAI-1 level in plasma may cause APE.The determination of tPA and PAI-1 concentrations in plasma plays an important role in the diagnosis of APE.